{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:41:22Z","timestamp":1777380082962,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>\n                    The Combination HIV Antiretroviral Rectal Microbicide-3 (CHARM-03) study was a randomized, open-label, crossover Phase 1 safety and pharmacokinetic (PK) study of oral maraviroc (MVC) and MVC 1% gel. At a single site, healthy HIV-uninfected men and women were enrolled and randomized to an open label crossover sequence of eight consecutive daily exposures to MVC 300\u2009mg dosed orally, MCV 1% gel dosed rectally, and MVC 1% gel dosed vaginally. Male participants received oral and rectal dosing and female participants received oral, rectal, and vaginal dosing. Assessments were undertaken at baseline and following each 8-day period and included collection of plasma, rectal\/cervical tissue (CT), and rectal\/endocervical\/vaginal fluids. Eleven men and nine women were enrolled. Two participants withdrew from the study before receiving study product. There were 25 adverse events, of which 24 were Grade 1 (G1) and one was G2 (unrelated). After eight doses, MVC was quantifiable in all samples following oral, rectal, or vaginal product administration. The highest drug concentrations in plasma, rectal tissue (RT), and CT were associated with oral, rectal, and vaginal drug delivery, respectively. There were significant reductions in tissue drug concentrations when rectal and cervical biopsies were incubated in media before tissue processing for PK (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u2009.0001). Only oral MVC was associated with limited protection in the rectal explant HIV challenge model (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    \u2009&lt;\u2009.05). There were no immunological changes in RT, and all products were acceptable to participants. In conclusion, all products were found to be safe and acceptable and did not induce local inflammation. The lack of\n                    <jats:italic toggle=\"yes\">ex vivo<\/jats:italic>\n                    efficacy demonstrated in study samples may be due to rapid disassociation of MVC from the explant tissue.\n                  <\/jats:p>\n                  <jats:p>ClinicalTrials.gov Identifier: NCT02346084.<\/jats:p>","DOI":"10.1089\/aid.2021.0096","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T01:12:03Z","timestamp":1628817123000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-8476","authenticated-orcid":false,"given":"Ian M.","family":"McGowan","sequence":"first","affiliation":[{"name":"Orion Biotechnology, Ottawa, Canada."},{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."},{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chawki","sequence":"additional","affiliation":[{"name":"INSERM, Paris, France."},{"name":"Department of Virology, H\u00f4pital Saint-Louis, Assistance Publique-H\u00f4pitaux de Paris, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Anton","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California Los Angeles, Los Angeles, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhonda M.","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."},{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarret C.","family":"Engstrom","sequence":"additional","affiliation":[{"name":"Orion Biotechnology, Ottawa, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa C.","family":"Rohan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."},{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaleab Z.","family":"Abebe","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Richardson-Harman","sequence":"additional","affiliation":[{"name":"Alpha StatConsult LLC, Damascus, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Siegel","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Reinhart","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Uxbridge, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Steytler","sequence":"additional","affiliation":[{"name":"International Partnership for Microbicides, Silver Spring, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Stall","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Kelly Government Solutions, Department of Health and Human Services, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."},{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-8262","authenticated-orcid":false,"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA."},{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy E.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Khanukova","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Johns Hopkins University, Baltimore, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-6217","authenticated-orcid":false,"given":"Ross D.","family":"Cranston","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Barcelona, Barcelona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30087-X"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004997"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000432449.30239.fe"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70315-8"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000039"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2344-7"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3181901ccf"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200103090-00017"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040339"},{"key":"e_1_3_6_11_2","first-page":"88","article-title":"Heterosexual transmission of human immunodeficiency virus: Variability of infectivity throughout the course of infection","volume":"148","author":"Leynaert B","year":"1998","unstructured":"Leynaert B, , Downs AM, , de Vincenzi I: Heterosexual transmission of human immunodeficiency virus: Variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol, 1998; 148:88\u201396.","journal-title":"European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010003"},{"key":"e_1_3_6_13_2","unstructured":"Organization WH: Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. Geneva World Health Organization 2012."},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002613"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09883-z"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32830891cf"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000209"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.90.7.1117"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2015.1069785"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8356453"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir725"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.185.4.621"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182a7a97a"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03140.x"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1319"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350901400514"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020209"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/655661"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0073"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-012-0148-2"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001108"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000769"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002038"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01204-13"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv334"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203183109"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0262"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318291f331"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126454"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060147"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.02.008"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.06.018"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181ae69c5"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir059"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30113-8"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004174"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125363"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2015.0315"},{"key":"e_1_3_6_49_2","first-page":"238","article-title":"Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305)","volume":"215","author":"Gulick RM","year":"2017","unstructured":"Gulick RM, , Wilkin TJ, , Chen YQ, et al.: Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (HPTN 069\/ACTG A5305). J Infect Dis, 2017; 215:238\u2013246.","journal-title":"J Infect Dis"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0231"},{"key":"e_1_3_6_51_2","unstructured":"Hartley O Offord R Engstrom J McGowan I: OB-002 (5P12-RANTES) is significantly more potent than other CCR5 antagonists in development for the treatment or prevention of HIV infection. Abstract A-1077-0069-00834. 10th IAS Conference on HIV Science Mexico City 2019. http:\/\/programme.ias2019.org\/Abstract\/Abstract\/834 accessed September2 2021."},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0010"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01729-19"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/aid.2021.0096","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0096","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/aid.2021.0096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:16:23Z","timestamp":1777367783000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/aid.2021.0096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1089\/aid.2021.0096"],"URL":"https:\/\/doi.org\/10.1089\/aid.2021.0096","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}